GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic
19 Jul 2024 //
FIERCE BIOTECH
GRO Biosciences Appointed Tracey Lodie as Chief Development Officer
18 Mar 2024 //
BUSINESSWIRE
GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs
27 Sep 2023 //
BUSINESSWIRE
GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship
11 Apr 2023 //
BUSINESSWIRE
GRO Bio Announces Addition of Nicole Paulk, PhD, to Scientific Advisory Board
07 Sep 2022 //
BUSINESSWIRE
GRO Biosciences to Present at 2022 BIO CEO & Investor Conference
03 Feb 2022 //
BUSINESSWIRE